Lv4
520 积分 2025-05-09 加入
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing
23天前
已完结
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review
23天前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
23天前
已完结
Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
23天前
已完结
The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
23天前
已完结
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
23天前
已完结
TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT
23天前
已完结
Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC
23天前
已完结
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China
1个月前
已完结
Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain
1个月前
已关闭
皖公网安备34019202002308
